KDR and neoplasm: Apatinib, a novel, small molecule, selective tyrosine kinase inhibitor (TKI), could inhibit multiple tumor-related kinases (TRKs), such as vascular endothelial growth factor receptor-2 (VEGFR-2), and induce apoptosis, suppressing tumor proliferation in multiple tumors (8).